Pulse Biosciences Showcases Nanosecond PFA Technology at AF Symposium 2025
Pulse Biosciences' Nanosecond PFA Technology Takes Center Stage at AF Symposium 2025
Pulse Biosciences, Inc. (Nasdaq: PLSE), a leader in bioelectric medicine, is set to showcase its groundbreaking Nanosecond Pulsed Field Ablation™ (nsPFA™) technology at the 30th Annual AF Symposium 2025. The event, taking place from January 16-18 in Boston, Massachusetts, will feature the nsPFA 360° Cardiac Catheter in both a late-breaking science session and a live case transmission.
Highlighting Clinical Advancements
The late-breaking clinical science session, scheduled for Friday, January 17th, will be led by Dr. Vivek Reddy. Titled "Pulsed Field Ablation Using a Compliant Circular Catheter Delivering Nanosecond Pulses to Treat Atrial Fibrillation," the session will review the outcomes of the first 30 patients treated with the nsPFA 360° Cardiac Catheter in a feasibility study conducted at Na Homolce Hospital.
On Saturday, January 18th, Dr. Petr Neuzil from Homolka Hospital in Prague, Czech Republic, will conduct a live case transmission. This session, titled "Nanosecond Pulsed Field Ablation for Atrial Fibrillation," will demonstrate the catheter's workflow efficiency for pulmonary vein isolation, utilizing the Abbott Ensite X 3D Mapping System for 3D navigation.
Commitment to Innovation
Paul LaViolette, Co-Chairman of Pulse Biosciences’ Board of Directors, expressed his enthusiasm for the company's progress, stating, "Having two renowned physicians showcase the clinical benefits of the differentiated mechanism of action and device at this vital AF scientific meeting is a strong testament to the team’s progress and the unique role of nsPFA." Pulse Biosciences is committed to advancing its nsPFA technology within the clinical community, with plans to initiate a U.S. IDE pivotal clinical study for the catheter in mid-2025.
About Pulse Biosciences
Pulse Biosciences is dedicated to developing innovative bioelectric medicine solutions that have the potential to significantly improve patient care. The company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue, offering a promising approach to treating atrial fibrillation and other conditions.
With its headquarters in Miami, Florida, and an office in Hayward, California, Pulse Biosciences continues to lead the way in health innovation, aiming to enhance the quality of life for patients worldwide.